Mesoblast (MESO) Other Non Operating Income (2016 - 2025)

Mesoblast (MESO) posted Other Non Operating Income of $10.3 million for Q4 2025, up 596.67% sequentially from $1.5 million in Q4 2023.

Mesoblast (MESO) Other Non Operating Income (2016 - 2025) Analysis & Trends

Mesoblast has reported Other Non Operating Income for 9 years, with the latest figure at $10.3 million in Q4 2025.

Quarterly Other Non Operating Income changed N/A year-over-year to $10.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.3 million (changed N/A YoY) and the FY2022 annual result came in at $5.9 million, up 486.88% from the prior year.
Other Non Operating Income grew to $10.3 million in Q4 2025 per MESO's latest filing, from $1.5 million in the prior quarter.
Over five years, Other Non Operating Income peaked at $10.3 million in Q4 2025 and troughed at -$401000.0 in Q3 2022.
A 4-year average of $2.2 million and a median of $1.5 million in 2022 frame the typical range for Other Non Operating Income.
The widest YoY moves for Other Non Operating Income: up 138.05% in 2021, down 185.54% in 2021.
Over 4 years, Other Non Operating Income stood at $2.2 million in 2021, then plunged by 31.55% to $1.5 million in 2022, then changed by 0.0% to $1.5 million in 2023, then soared by 596.67% to $10.3 million in 2025.
According to Business Quant data, Other Non Operating Income over the past three periods registered $10.3 million, $1.5 million, and $1.5 million for Q4 2025, Q4 2023, and Q1 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Mesoblast	2.01 Bn	1.87 Bn	-

Download Data